Physician profile
Caroline Simon
NPI 1790903524
$10,061.55
in general payments reported to CMS, 2019-2025
27 companies · $896 in 2025
The $896 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $258 · 2021: $370 · 2022: $371 · 2023: $2,481 · 2024: $5,518 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,253 · Food and Beverage: $2,571 · Travel and Lodging: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,253.00 |
| Food and Beverage | $2,571.13 |
| Travel and Lodging | $2,070.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,778.78 | 2020-2024 | |
| Transmedics, INC. | $1,451.00 | 2023 | Organ Care System |
| Ethicon INC. | $620.28 | 2024-2025 | |
| Abbvie INC. | $410.28 | 2023-2024 | Avycaz, Teflaro |
| Veloxis Pharmaceuticals, INC. | $351.06 | 2019-2023 | Envarsus |
| Mallinckrodt Hospital Products INC. | $263.94 | 2023-2025 | Terlivaz |
| Medtronic, INC. | $248.74 | 2022 | |
| Merck Sharp & Dohme LLC | $245.38 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Eisai INC. | $192.23 | 2022-2023 | |
| Biom'Up France Sas | $189.05 | 2021 | |
| Alexion Pharmaceuticals, INC. | $173.80 | 2023-2025 | Ultomiris, Soliris |
| Dilon Technologies, INC. | $167.97 | 2025 | Hemoblast Bellows |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.12 | 2023-2025 | Xifaxan |
| Kci USA, INC. | $100.28 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $100.00 | 2024 | Utaswako Afp-L3 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $95.47 | 2025 | Livtencity |
| Davol INC. | $94.36 | 2022-2023 | Phasix Mesh |
| Madrigal Pharmaceuticals | $65.11 | 2025 | Rezdiffra |
| Integra Lifesciences Corporation | $64.64 | 2022-2023 | Codman Hakim, Duraseal Exact Spinal Sealant System, Codman Certas |
| Smith+Nephew, INC. | $61.98 | 2023-2024 | Stravix Pl, Oasis |
| Baxter Healthcare | $61.11 | 2023-2024 | Perclot |
| Intercept Pharmaceuticals, INC. | $60.07 | 2025 | |
| Kerecis Limited | $40.17 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Melinta Therapeutics, LLC | $34.87 | 2024 | Rezzayo |
| Incyte Corporation | $23.11 | 2024 | Pemazyre |
| Sirtex Medical INC | $22.75 | 2023 | Sir-Spheres Microspheres |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.